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a b s t r a c t
Clostridium chauvoei is the etiologic agent of blackleg in cattle, inducing fever, severe myonecrosis,
oedemic lesions and ultimately death of infected animals. The pathogen often results in such rapid death
that antibiotic therapy is futile and thus vaccination is the only efficient strategy in order to control the
disease. The b-barrel pore forming leucocidin Clostridium chauvoei toxin A (CctA) is one of the best
characterised toxins of C. chauvoei and has been shown to be an important virulence factor. It has been
reported to induce protective immunity and is conserved across C. chauvoei strains collected from diverse
geographical locations for more than 50 years. The aim of this study was to identify the location of the
CctA toxin during liquid culture fermentation and to use CctA to develop an in vitro assay to replace the
current guinea pig challenge assay for vaccine potency in standard batch release procedures. We report
that CctA is fully secreted in C. chauvoei culture and show that it is found abundantly in the supernatant
of liquid cultures. Sera from cattle vaccinated with a commercial blackleg vaccine revealed strong
haemolysin-neutralizing activity against recombinant CctA which reached titres of 1000 times 28 days
post-vaccination. Similarly, guinea pig sera from an official potency control test reached titres of 600
times 14 days post-vaccination. In contrast, ELISA was not able to specifically measure anti-CctA anti-
bodies in cattle serum due to strong cross-reactions with antibodies against other proteins present pre-
vaccination. We conclude that haemolysin-neutralizing antibodies are a valuable measurement for
protective immunity against blackleg and have the potential to be a suitable replacement of the guinea
pig challenge potency test, which would forego the unnecessary challenge of laboratory animals.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Clostridium (C.) chauvoei is the causative agent of blackleg also
referred to black quarter and quarter evil, a severe infectious
disease predominately affecting cattle [1]. It causes a fulminant
myonecrosis, which rapidly leads to the death of the animal [2e4].
Blackleg causes significant losses in livestock production globally
due to its high lethality rate [1,3]. C. chauvoei is a strict anaerobic,
spore forming, monomorphic and motile Gram-positive bacterium
that is spread worldwide [5]. Grazing ruminants become infected
due to C. chauvoei spores persistently contaminating the soil of
pastures either from perished animals or via manure [4,6]. Despite
the fact that blackleg is one of the oldest clinically known diseases
affecting cattle, the exact mechanisms of its pathogenesis remain
unclear [1,3,7e10]. Similarly, knowledge gaps also exist concerning
the role of the toxins and virulence factors produced by C. chauvoei
but various virulence factors have been recently characterised [1,3]
and genomic studies have contributed to a better understanding of
virulence in C. chauvoei [5,11]. The best characterised virulence
Abbreviations: CctA, Clostridium chauvoei leucocidin toxin A; rCctA-NusA, re-
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factor is Clostridium chauvoei toxin A (CctA) belonging to the b-
barrel pore forming leucocidin family [12]. This factor has been
shown to be the main cytotoxic and haemolytic agent of C. chauvoei
[13]. Along with a highly active DNAse, hyaluronidase and sialidase,
they seem to constitute the central virulence arsenal of C. chauvoei
[1,3,7,13e15]. Furthermore, flagella have also been reported to be
involved in the pathogenesis of C. chauvoei infections [11,16e23].
C. chauvoei is one of the most toxic of the clostridial species,
often inducing such a rapid death in animals that antibiotic therapy
tends to be a fruitless treatment for blackleg. However, vaccines
containing C. chauvoei valences are highly successful at preventing
the disease and are used worldwide to control blackleg [3,24]. Only
sporadic outbreaks of blackleg occur globally each year [1]. Vac-
cines against blackleg have been available since the 1930s and
consist of chemically inactivated bacteria and bacterial culture su-
pernatants from relatively old strains [24]. Even though the current
blackleg vaccines, consisting of bacterin and toxoided culture su-
pernatants are effective, it is not clear which antigens in the current
formulations actually provide the protection. Indeed, identity of the
protective antigens as well as their location has never been
conclusively resolved. For a long time it was proposed that flagella
and various outer membrane proteins were the protective immu-
nogens against C. chauvoei infections [18e20,25] while more
recently it was reported that the extracellular proteins of
C. chauvoei are necessary for protection [26].
As standard procedure, the potency of vaccine batches must be
monitored by a challenge model in guinea pigs [27]. In this test, the
vaccine under assessment is administered to at least 10 guinea pigs,
which are later challenged with a virulent strain of C. chauvoei
alongside a non-vaccinated control group of guinea pigs. For the
test to be valid, all of the control animals must diewithin three days
and for the vaccine to pass the test, at least 90% of the vaccinated
guinea pigs must survive for at least five days post-challenge. This
procedure induces great distress in the animals.
CctA is fully conserved between C. chauvoei strains isolated
worldwide [5] and it was recently shown that a recombinant
version of the toxin (rCctA) provided full protection in the guinea
pig infectionmodel used for official potency tests as part of blackleg
vaccine batch release procedures [13]. Furthermore, serum from
guinea pigs vaccinated with inactivated rCctA neutralized both the
cytotoxic activity of C. chauvoei to embryonic calf nasal epithelial
cells (ECaNEP) and the haemolytic activity of C. chauvoei culture
supernatants [13]. Hence, CctA must be considered as one of the
main protective antigens in vaccines against blackleg [3]. Our aim
here was to further characterize the leucocidin CctA and make it
central to the development of an in vitro assay to potentially replace
the current guinea pig challenge potency test as standard for
blackleg vaccine batch releases. This would remove the need for
experimental infections of animals.
2. Materials and methods
2.1. Cattle information, vaccination and serum preparation
Ten cattle were vaccinated with a single dose of the vaccine
Bovilis® Blackleg (ad us. vet. MSD Animal Health GmbH,
Switzerland) according to the instructions of the manufacturer. The
vaccination protocol consists of a single subcutaneous application
supra scapulae of Bovilis® Blackleg. One vaccine dose is 2mL and
consists of 2.5 108 inactivated bacteria and toxoid of the five
C. chauvoei strains (655, 656, 657, 658 and 1048), 400mg
aluminium hydroxide (adjuvants), 0.013% thiomersal (conserva-
tives) and traces of formalin (inactivation), according to Swiss-
medic, the registration office of Switzerland. Blood samples were
taken from the vena caudalis mediana with standard vacutainers
prior to the vaccination and once per week for 4 weeks post-
vaccination. Blood samples were immediately cooled to 4 C and
serum was separated by coagulation and centrifugation using
standard procedures. The decision to vaccinate 10 animals was
calculated using the Stata statistics software (StataCorp, 2011, Stata
statistical software: release 12.0. Statcorp LP, College Station, TX,
USA) using the following parameters: alpha, 0.05; power, 0.80;
number of follow-up measurements 4; correlation between follow
up measurements, 0.70. The 10 cows used in this study are part of a
herd of 25 cows owned by the department of Farm Animals of the
University of Zürich. This herd is used for educational purposes at
the Veterinary faculty. All cows were pluripar and in the age range
of 3e8 years. The breeds were Brown Swiss and Holstein Friesian.
The cowswere kept in a tie barn and fed hay and grain but no silage.
The herd was established in 1970, it has no history of blackleg
disease and this was the first time that the dams were vaccinated
against blackleg. This study was conducted under the research
animal approval of the Veterinary Office of the canton of Zurich
(permission number eTV 27763).
2.2. Serum of vaccinated guinea pigs
Serum from 10 guinea pigs taken pre- and 14 days post-blackleg
vaccination was kindly donated to JF by the Swiss Federal vaccine
control authority after performing an official blackleg vaccine
control test according to international standards [27].
2.3. C. chauvoei culturing conditions and preparation of bacterial
supernatants and cell pellets
C. chauvoei reference strain JF4335 [5,28] which was fully
genome sequenced (GenBank/EMBL accession number LT799839),
was grown anaerobically in Brain Heart Infusion (BHI) broth (Oxoid
Microbiology products, Thermo Scientific, Waltham, MA, USA)
supplemented with 0.05% L-cysteine (Sigma-Aldrich chemical, St.
Louis, MO, USA) or on standard blood agar medium (Thermo Sci-
entific™ R01198, Blood Agar TSA with 5% Sheep Blood Medium) in
an anaerobic chamber at 37 C for up to 72 h.
2.4. Production of recombinant antigenic domain of CctA
Haemolytically active recombinant CctA protein fused to the
E. coli NusA protein which acts as a stabilizer (rCctA:NusA) was
produced as previously described [13]. To express an antigenically
active but not haemolytically active CctA derivative for analytical
purposes, we designed a peptide based on the central domain of
CctA, named CctA-cent. The antigenic domain of CctA was deter-
mined based on hydrophilicity scores and the charged amino acid
content in the peptide structure [29]. To express the CctA-cent
peptide, the gene fragment for the antigenic central fragment of
CctA (AA 177e271) was amplified by PCR using genomic DNA of
strain JF4335 and primers: CctAcentF CATCCATGGGCA-
TAACTAAAAGTATCCCAACTAATC and CctAcentR CATGGATCCA-
TATTGATCATTAAAACGATTATATTC (letters in italics are additional
nucleotides for NcoI and BamHI recognition and to ensure fusion
with the poly-His site in the pET-HIS1 plasmid). The generated PCR
fragment was cloned into pET-HIS1 [30] using the restriction sites
NcoI and BamHI. Expression and purification of rCctA-cent was
performed as described before [30] using BL21 (DE 3) E. coli cells
yielding a peptide of 18.7 kDa.
2.5. Immunological detection of CctA
C. chauvoei cells were grown for 24 h to mid-log phase as
specified in section 2.3 above, followed by centrifugation at
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100000g for 30min at 4 C. The bacterial pellet was re-suspended
in a volume of Phosphate-Buffer Saline (PBS) (10mMNa-phosphate
pH 7.4, NaCl 144mM) equal to the volume of the collected super-
natant from any given culture and both fractions weremixed 1:1 (v/
v) with SDS-PAGE loading buffer (65.8mM Tris-HCl, pH 6.8, 26.3%
(w/v) glycerol, 2.1% SDS, 0.01% bromophenol blue) containing 5% b-
mercapto-ethanol. The samples were separated by SDS-PAGE. Re-
combinant CctA [13] and a purchased recombinant (r)CctA
(Antibodies-online.com, PX-P3067-20) were used as positive con-
trols. The proteins were transferred onto polyvinylidene diflouride
(PVDF) membranes (Millipore, IPVH10100) using the Trans-Blot SD
semidry transfer system (Bio-Rad) at 18 V in Towbin transfer buffer
(25mM Tris, 192mM Glycine and 20% (v/v) methanol). The mem-
branes were blocked for 30min using TBST (20mM Tris, 137mM
NaCl and 0.1% Tween-20 detergent, pH 7.6) with 5% skimmed-milk
powder and then probed with rabbit anti-CctA serum [13] diluted
1:1000 in TBST and for 2 h at room temperature with phosphatase
labelled goat anti-rabbit (KPL 4751-1516) diluted 1:5000 in TBST.
The signals were detected by incubating the blot in fresh alkaline
phosphatase substrate buffer (100mM Tris-HCl, pH 9.5; 100mM
NaCl; 5mMMgCl2) containing BCIP (Roche 11585029001) and NBT
(Roche 10760994001) staining solutions (Fig. 1). The blots shown in
Fig. 2 were performed as stated above except, rCctA-cent was
loaded in to one lane spanning a 15% SDS polyacrylaminde gel, the
PVDF membrane was cut into equally sized strips and probed with
the serum (diluted 1:50 using TBST) collected at day 0 and day 28
post-vaccination for each cow, followed by incubation with a
monoclonal anti-bovine IgGalkaline phosphatase secondary
antibody produced in mouse (Sigma-Aldrich, #A7554), diluted
1:3000 using TBST.
2.6. Triton X-114 membrane protein extraction for C. chauvoei
C. chauvoei JF4335 cells were grown as above for 24 h and 1mL
was centrifuged at 100000g for 30 min at 4 C, the supernatant
and bacterial pellet were treated as described above. After washing
with PBS, the bacterial pellet was re-suspended in 900 mL cold
sterile TS þ buffer (154 mM NaCl, 10 mM Tris, pH 7.4 þ cOmplete
EDTA Protease inhibitor cocktail (Roche, 11873580001). Triton X-
114 fractionation was performed according to Bordier [31].
2.7. Tryptic shaving experiments
JF4335 C. chauvoei cells were grown as above for 24 h and
centrifuged as above. Four 2mL samples were prepared from the
same culture. The bacterial pellet of sample 1 was re-suspended in
cold buffer (20mM Tris-HCl, 150mM NaCl, pH 7.6) equal to the
volume of the collected supernatant from any given culture. Sample
2 was treated as samples 1, except the cells were washed before
their re-suspension. The bacterial pellet of sample 3 was re-
suspended in 2mL of incubation buffer (20 mMTris-HCl, 150mM
NaCl, 10mM CaCl2 and 0.5M sucrose) supplemented with 10 mg
trypsin re-constituted in 100 mL acetic acid (Promega V5111) and
incubated at 37 C for 2 h. Sample 4 was treated as sample 3, sup-
plemented with 100 mL acetic acid but lacking trypsin. Samples 3
and 4 were centrifuged at 100000g for 15min at 4 C. The super-
natants were retained, and the cells were re-suspended in cold
buffer (20mM Tris-HCl, 150mM NaCl, pH 7.6). The cells and su-
pernatant samples were mixed 1:1 with 2  sample buffer and
SDS-PAGE followed by immunoblotting was performed as detailed
above.
2.8. LC-MS/MS analysis and data interpretation
SDS-PAGE and protein transfer to PVDFmembrane of C. chauvoei
samples was performed as described above. The membrane was
thoroughly washed in PBS and the middle section of the membrane
was retained at 4 C. The membrane on either side was used for
immunoblotting as described before. The probed membrane and
middle clean membrane were aligned, and areas of the non-blotted
membrane were excised using a sterile scalpel according to the
bands of interest in the immunoblotted membranes. The excised
membrane pieces were further cut into six 1mm3 pieces and
transferred to a micro-centrifuge tube. The membranes were
blocked with 100 mL 0.5% PVP-40, reduced with 50mMDTT/50mM
Tris pH 8.0 and alkylated with 50mM IAA/50mM Tris pH 8.0 prior
to trypsin (Promega, V511A) digestion for 6 h at 37 C. The peptides
were extracted by adding 10 mL of 20% formic acid and transferred
in a new tube.
Each sample was analysed by nano-liquid chromatography
tandemmass spectrometry at the Proteomics&Mass Spectrometry
Core Facility of the University of Bern using a Fusion LUMOS mass
spectrometer (Thermo Fischer, Bremen; Germany) via a Nano spay
ESI source, or for a second set of samples on a QExactive Quadru-
pole Orbitrap mass spectrometer (Thermo Fisher Scientific) [32]
(see Table 1).
2.9. Analysis of CctA haemolytic activity
Recombinant (r)CctA:NusA was produced as described previ-
ously [13] or purchased (Antibodies-online.com, PX-P3067-20). The
haemolytic activity of rCctA:NusA was determined by 2-fold serial
dilution in 0.9% NaCl - 10mM Tris hydrochloride (pH 7.5) buffer and
mixing 100 mL of each dilutionwith 100 mL of 1% sheep erythrocytes
(approximately 7 107 erythrocytes/mL) (Oxoid Limited, Thermo
Scientific, Basingstoke, Hampshire, England UK; SR0051C). The
mixtures were incubated for 2 h at 37 C and then sedimented by
centrifugation at 50000g for 15min. The optical adsorption at
540 nm of the supernatants was measured using an ELISA reader.
Negative control samples contained equal volumes of buffer and
erythrocyte suspensions. One haemolytic unit (HU) is defined as
the amount of material that fully lyses a 0.5% sheep erythrocyte
suspension under the assay conditions described above.
2.10. Haemolysin neutralization assay
The haemolysin neutralization capacity of bovine and guinea pig
serum was measured by pre-incubation of 100 mL of rCctA:NusA
titrated to 1 HU/100 mL with 10 mL of two-fold serially diluted
bovine serum samples from vaccinated and non-vaccinated ani-
mals prior to addition to 100 mL of 1% sheep erythrocytes for
10min at 37 C for 10min. The neutralizing capacity is given by the
maximum serum dilution that results in full neutralization of the
haemolysis under the given experimental conditions.
3. Results
3.1. Leucocidin CctA is fully secreted by C. chauvoei and not
retained in or on the bacterial surface
Blackleg vaccines are based on a mixture of detoxified culture
supernatant of C. chauvoei and inactivated bacteria but there is no
conclusive information concerning the protective antigens and
where they reside in this vaccine. In a previous study, we charac-
terised CctA as a major virulence factor of C. chauvoei and
demonstrated that it is one of the main protective antigens in
vaccines against blackleg [13]. However, the exact location of the
CctA toxin in liquid culture has never been determined. To this end,
we employed a variety of biochemical methods to address the exact
location of CctA in liquid culture; cell membrane bound, totally
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secreted or a combination of both. First, to demonstrate the spec-
ificity of our anti-CctA antibody [13] which provides the basis of our
experiments, we loaded the recombinantly generated CctA pro-
duced in this study, encompassing the central antigenic domain of
CctA-cent (rCctA-cent comprising amino acids (AA) 177e271), with
a predicted molecular mass of 18.7 kDa and a commercially pur-
chased recombinant mature CctA (AA29-317) with a stated mo-
lecular mass of 59.53 kDa on to a 15% SDS-polyacrylamide gel
followed by Western blotting. Immunoblotting analysis shows that
the anti-CctA antibody was able to specifically detect both the
partial recombinant protein rCctA-cent and the tagged mature
rCctA at the correct molecular masses (Fig. 1A). Therefore, inde-
pendent mid-log C. chauvoei bacterial cultures were centrifuged
and the bacterial pellet were resuspended in an equal volume of
buffer as the volume of collected supernatant. Both the cell lysate
and supernatant were subjected to SDS-PAGE followed by
Fig. 1. Immunoblot analysis of recombinant CctA and of antigens from C. chauvoei liquid cultures. A. recombinant rCctA-cent representing the central part (AA 117e271) and
recombinant mature size NusA-6xHis tagged CctA fusion protein were subjected to SDS-PAGE, followed by immunoblotting with monospecific rabbit anti CctA hyper-immune
serum. The expected molecular masses of 18.7 kDa for rCctA (AA177-271) and 59.52 kDa rCctA (AA30-317eNusA-6xHis) were detected in lanes 1 and 2, respectively. B. Three
independent C. chauvoei cultures (1e3) were separated in to cells (lanes 1, 3 and 5) and supernatant (SN; lanes 2, 4 and 6) by centrifugation. The cells were re-suspended in PBS to
the equal volume of the collected supernatant. Each fraction was separated by SDS-PAGE followed by immunoblotting using anti-CctA serum. Recombinant CctA (Antibodies online.
com) served as a positive control for the anti-CctA specificity (lane 7). C. Triton X-114 phase partitioning. C. chauvoei cells were partitioned into an aqueous fraction (AQ phase; lane
2) containing hydrophilic proteins and a TX-114 detergent fraction (TX phase; lane 3) containing amphiphilic integral membrane proteins. The total cells (lane 1) along with the AQ
and TX phases were separated by SDS-PAGE followed by immunoblotting using anti-CctA serum. D. Tryptic shaving of C. chauvoei cells. Four 2mL samples from a culture of
C. chauvoei culture were used in this experiment. Sample 1 was separated in to cells (lane 1) and supernatant (SN) (lanes 2). Sample 2 was treated as sample 1 except the cells from
2mL of C. chauvoei culture were washed (lanes 3 & 4). Sample 3 was treated as sample 2 except the washed C. chauvoei cells were treated with trypsin for 120min (lane 4) Samples
4 was treated as sample 3 except trypsin was omitted from the incubation buffer (lane 7). Samples 3 and 4 were centrifuged after the incubation and the supernatants were
collected (lanes 6 and 8, respectively) All designated samples were subjected to SDS-PAGE followed by immunoblotting using anti-CctA serum.
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immunoblotting with the anti-CctA. Fig. 1B revealed, at first glance,
that CctA appears to be secreted in to the culture supernatant as
well as being located on the cells since we detected a signal around
35 kDa in the supernatant corresponding to endogenous mature
CctA protein [13] and another signal at 45 kDa in the cell lysate
(Fig. 1B).
Triton X-114 partitioning was performed to investigate if this
45 kDa protein detected using anti-CctA is located on the cell
membrane. Phase separation of integral membrane proteins in
Triton X-114 solution using C. chauvoei cells from a mid-log culture
followed by resolving the samples on SDS-PAGE and probing with
anti-CctA demonstrated that the 45 kDa signal is most likely
membrane associated since the signal was observed in the deter-
gent fraction (TX) and not in the aqueous fraction (AQ) (Fig. 1C).
This detergent based method of fractionation is limited in that it
may be cross-contaminations of the separated phases. Therefore, to
overcome this limitation and also to provide insight into the to-
pological organisation of this protein detected by the CctA antibody
on the cell surface, we employed tryptic shaving experiments, a
technique established by others to examine the bacterial cell
Fig. 2. Immunoblot analysis of cattle serum before and after vaccination with Bovilis® Blackleg. Immunoblots contain purified recombinant CctA-cent antigen (18.7 kDa) and
were immunoblotted with serum from cattle taken pre-(0) or 28 days post-vaccination (serum dilution 1:50). Sera from 10 animals are denoted at the top of the blots.
Table 1
Results of mass spectrometry analysis using C. chauvoei cell and supernatant components to identify potential proteins immunodetected using anti-CctA.
Cell fractionation, SDS-PAGE, immunoblotting, mass spectrometry and data acquisition were performed as stated in the materials and methods section 2.8. PMSS is Protein
Match Score Summation wherein all scores from peptide spectral matches (PSM) to one particular protein are added up irrespective of the fact if a peptide was identified
several times, with or without modifications. PSM defines a potentially correct interpretation of a single fragment spectrum. Coverage is stated in percentage (%) and protein
mass is given in Daltons (Da).
PMSSi Cover-age (%) PSM Pep tides Protein Mass (Da) Description
A. Supernatant
1. 298.39 46.06 51 11 35572.50 Putative CctA
B. Cells
2. 2617.952 71.03 235 27 43646.7 Elongation factor Tu
3. 2374.507 70.94 194 23 43822.2 Flagellin
4. 518.7743 73.27 50 25 46866.1 Putative Pyrimidine-nucleoside phosphorylase
5. 708.3453 58.31 71 23 49436.9 Putative ABC transporter substrate-binding protein
6. 496.5089 73.4 51 23 42050.2 Phosphoglycerate kinase
7. 308.5164 62.89 31 16 42742.6 Phosphopentomutase
8. 258.9276 48.37 26 15 44860.4 Glucose-1-phosphate adenylyltransferase
9. 148.2079 36.98 17 12 43932.1 3-oxoacyl-[acyl-carrier-protein] synthase 2
10. 171.114 38.74 19 10 45590.9 Putative FAD-dependent pyridine nucleotide-disulfide oxidoreductase
11. 101.7717 39.9 12 11 43733.8 Putative Electron transfer flavoprotein, alpha subunit-
12. 96.14735 22.71 12 9 45088.9 Gamma-glutamyl phosphate reductase
13. 65.68321 27.94 8 7 46089.2 Putative Aminopeptidase II
14. 93.78725 21.65 12 7 45569.4 Putative Dihydroorotate dehydrogenase family protein
15. 75.39014 20.49 9 6 41174.5 Putative Ribosomal protein S1
16. 51.20397 17.75 6 6 43278.5 Probable tRNA sulfurtransferase
17. 56.38388 14.62 7 6 47419.6 M18 family aminopeptidase
18. 40.69621 14.53 4 4 45546.5 Tyrosine–tRNA ligase
19. 44.87383 15.46 5 4 42997.4 Putative NADH-dependent butanol dehydrogenase
20. 27.22858 12.17 3 3 36671.6 Uncharacterized protein
21. 25.59351 8.71 2 2 40994.4 Putative Acyl-CoA dehydrogenase
22. 24.89473 7.95 3 3 47687.0 Histidine–tRNA ligase
23. 22.24853 8.36 3 3 43457.9 Putative UDP-N-acetylglucosamine 2-epimerase
24. 29.65345 6.41 4 3 44337.3 Putative Flavo-diiron protein FprA1
25. 19.29608 9.42 2 2 40714.1 GDP-mannose 4,6-dehydratase
26. 19.12764 6.16 2 2 45913.2 Putative Hypothetical oxidoreductase YeiT
27. 16.68868 9.94 2 2 35732.8 Glyceraldehyde-3-phosphate dehydrogenase
28. 14.13798 11.75 2 2 43535.1 Aspartokinase
29. 16.12659 6.28 2 2 47004.6 Enolase
30. 15.671 5.79 2 2 42530.6 Putative perosamine synthetase
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surface proteome [33e36]. Washed C. chauvoei cells were incu-
bated with trypsin and we found that the 45 kDa signal was
reduced upon trypsin treatment compared to cells incubated using
the same experimental conditions, except lacking trypsin (Fig. 1D).
Collectively, these results indicate that the protein detected by anti-
CctA in C. chauvoei cell lysates is cell membrane located and can be
shaved from the surface using trypsin.
To conclusively identify this C. chauvoei membrane protein, we
performed on-membrane tryptic digestion of the proteins corre-
sponding to the anti-CctA detected bands in the cell lysate and
supernatant shown in Fig. 1B, followed by mass spectrometry (MS)
analysis. This method is preferable to in-gel enzymatic digestion
followed by MS where trypsin may have limited accessibility to
proteins implanted into the gel and there is a low recovery of hy-
drophobic digested proteins from SDS-polyacrylamide gels [37].
The MS results showed that the band detected using C. chauvoei
supernatant samples is unequivocally CctA at a molecular mass of
35.57 kDa andwas the only protein identified (Table 1). However, to
our surprise, the protein that we observed in the cell lysate fraction
likely belongs to C. chauvoei flagellum or elongation factor Tu. In
fact, over 20 protein were identified using the membrane pieces
corresponding to the proteins identified in the cell lysate using
anti-CctA. However, elongation factor Tu (EF-Tu) and Flagellin
(43.65 and 43.82 kDa, respectively) were by far top of the list in
terms of Protein Match Score Summation (PMSSi), coverage and
total number of peptides (Table 1). Therefore, taking into account
the TX114 experiments in Fig. 1C, the anti-CctA generated signal
using C. chauvoei cell lysates is most likely is due to a non-specific
cross-reaction of the rabbit serum with flagellin. EF-Tu is an
abundant protein involved in multiple cellular functions and is
found both in the cells and on the cell surface [38] and thus would
be in both the TX and AQ phase of such an experiment. Indeed,
commercially purchased rabbit serum resulted in the same signal
as seen in Fig. 1B using the cell lysate samples (Supplementary
Fig. 1). We conclude that CctA is completely secreted into the su-
pernatant of C. chauvoeimid-log cultures and does not appear to be
retained on or in the cell membrane.
3.2. Serological cross-reactions of CctA
Based upon our knowledge from previous studies and the data
above increasing our understanding of CctA, we made it central to
establishing a lab-based test for assessing vaccine potency with the
ultimate aim of replacing the current guinea pig challenge test.
Thus, we sought to develop a suitable in vitro immunoassay to
measure the antibody response induced by CctA after vaccination
against blackleg. In our initial attempt, we generated purified re-
combinant CctA corresponding to the central amino acids (AA) of
CctA (rCctA-cent: see section 2.4 and Fig. 1A) and used this as an
antigen to develop an immunoassay to measure specific antibody
responses post blackleg vaccination. However, our approach, even
after optimisations, to quantitate the induction of specific anti-
bodies towards CctA in cattle vaccinated for the first time with a
commercial blackleg vaccine (full cattle, vaccination procedure and
exact vaccine details are stated in section 2.1) was unsuccessful. In
brief, an indirect ELISA prepared with purified rCctA-cent did not
produce specific signals for vaccinated animals since non-
vaccinated animals showed high background signal (data not
shown). To remedy this, we attempted a variety of peptides based
around the central domain of CctA but the specificity was not
improved. Immunoblotting with rCctA-cent as an antigen
confirmed these findings since sera from vaccinated cattle
compared to sera taken pre-vaccination showed virtually identical
reactions on immunoblots (Fig. 2). Dilution of the cattle sera from
the 10 cows did not improve the specificity, as signals from both the
pre and post-vaccination sera reduced uniformly upon dilution. The
same results were obtained with rabbit and guinea pig sera that
were positive in the CctA ELISA or immunoblots prior to vaccination
(data not shown). BLASTp analysis of the amino acid sequence of
rCctA revealed similarity of the peptide with proteins of several
Gram-positive bacteria, in particular: the b-channel forming cyto-
lysin of Clostridium septicum (77% AA identity), the a-haemolysin of
Clostridium botulinum (65% identical aa) and the b-barrel channel
forming cytolysin NetE of Clostridium perfringens (56% AA identity).
Hence, such widespread antigens belonging to the b-barrel channel
forming protein family [12] may be responsible for the observed
cross-reactions of sera from non-vaccinated and non-infected
cattle.
3.3. Vaccinated cattle and guinea pigs induce neutralizing
antibodies against the haemolytic activity of r-CctA
C. chauvoei cultivated on blood agar medium shows a very
strong haemolytic halo (Fig. 3) and this has been shown to be due to
CctA [13]. Using this simple observation, we tested if our anti-CctA
antibody would be able to neutralize the strong haemolysis due to
secreted CctA. Thus, C. chauvoei was spread on to blood agar and
anti-CctA, anti-rabbit serum, as a control since anti-CctA was pro-
duced in rabbit and a PBS control to ensure aseptic technique, were
dropped in equal volumes onto defined areas of the blood agar
before incubation (Fig. 3). Compared to PBS and anti-rabbit serum,
anti-CctAwas able to completely neutralize the activity of CctA and
thus no haemolysis was observed in the defined anti-CctA droplet
areas (Fig. 3). In fact, we observed that the addition of anti-CctA
seemed to inhibit growth of the bacteria indicating that sub-
stances of lysed erythrocytes are required by C. chauvoei for effi-
cient growth on this medium. Therefore, given this clear result and
the observed problematic serological cross reactions associated
with the ELISA assay, we decided to establish a haemolysis-
neutralizing assay. The assay that we developed is based on hae-
molytically active rCctA:NusA (see section 2.4 for details) [13]. In
this assay (explained in sections 2.9-2-10), sera of all cattle and
guinea pigs taken prior to vaccination revealed virtually no
haemolysin-neutralization activity. Two weeks post-vaccination,
the neutralizing titres started to rise in all cattle and at 4 weeks
post-vaccination they had reached titres between 1000 and 2000 in
all 10 animals vaccinated (Fig. 4). On average, vaccination of cattle
with a commercial vaccine resulted in neutralization titres of 1000
four weeks post-vaccination (Fig. 5A). Similarly, sera from guinea
pigs taken at 14 days post-vaccination scored neutralization titres
of 600 (Fig. 5B). These results demonstrate the high specificity of
this in vitro assay for the determination of neutralizing sero-
conversion to CctA in both target animals and experimental ani-
mals used for standard blackleg vaccine potency tests.
4. Discussion
Vaccines against C. chauvoei have been used for many decades
and continue to be a successful preventive measure against
blackleg. However, there is relatively little knowledge regarding the
identity of the protective antigens, where they reside, and crucially,
how to measure these antigens conferring protection to the
vaccination as an assessment of vaccine potency. CctA was shown
to be the main virulence factor of C. chauvoei and recombinant CctA
used as a vaccine showed protective immunity in the standard
guinea pig challenge potency assay which is used internationally
for blackleg vaccine batch release [27]. To extend our characteri-
sation of CctA, we analysed anaerobic liquid culture of C. chauvoei,
equally split into culture supernatants and sedimented cells after
exponential growth of C. chauvoei in axenic medium.We found that
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CctAwas fully secreted and that no CctA appeared to be retained by
the bacterium (Fig. 1B). Indeed, the only band observed in the su-
pernatant by immunoblotting with anti-CctA was confirmed to be
CctA by mass spectrometry (Table 1). This is in full correlation with
the strong and large haemolytic halo caused by the haemolytic-
toxic activity of CctA that is typically found around the tiny col-
onies of C. chauvoei on standard blood agar solid medium, which is
used in common bacterial diagnostics (Fig. 3). It can be speculated
that a rapid and thorough secretion of the b-barrel channel forming
CctA toxin which has a very strong pore forming activity [3] is
necessary, otherwise it would interact with the membrane of the
growing bacterium and potentially interfere with growth of the
organism.
An antigen that was initially thought to represent cell-bound
CctA, based on our immuno-blotting experiments using the cell
fraction (Fig. 1BeD) was clearly identified as a membrane compo-
nent of C. chauvoei and according to our mass spectrometry results,
it is most likely flagellin or EF-Tu (Table 1). Both of these proteins
are inherent antigens of many commensal as well as pathogenic
bacteria which due to their conserved structures reveal strong
antigenic cross-reactions across species level. This was further
supported by the fact that immunoblotting using standard rabbit
serum also resulted in the same 43 kDa antigen of C. chauvoei cells
(Supplementary Fig. 1). The data presented here is in line with a
recent study from Jayaramaiah and colleagues who investigated
C. chauvoei cell surface associated proteins using various prote-
omics techniques [39]. They did not find CctA to be cell surface
bound and although we did not have the same widespread prote-
omics approach, we found many of the same proteins in the range
of 35e50 kDa such as flagellin, Electron transfer flavoprotein
components, ribosomal proteins and Enolase (Table 1). A deviation
from their study is that we clearly identified cell associated EF-Tu
(Table 1) but this interesting finding correlates very well with the
multitude of reports showing EF-Tu to be at the cell surface of many
Gram-negative and -positive pathogenic bacteria where it appears
to have various moonlighting activities such as involvement in host
cell binding [34,40e48]. Some years ago, EF-Tu was identified as
being an antigenic C. perfringes protein which can be used as a
target antigen to detect serum antibodies in chicken with or
without clostridial infections [48]. In fact, most of the cell surface
proteins that we identified correlate very well to the major func-
tional groups of proteins that have been reported in recent years as
moonlighting proteins in pathogenic bacteria [38].
In our first attempt to assess the induction of CctA specific an-
tibodies in vaccinated cattle, we produced and purified the anti-
genic 18.7 kDa central domain of CctA as a recombinant peptide by
standard recombinant gene technology in E. coli. This rCctA-cent
peptide showed strong serological cross reactions with serum
from non-vaccinated cattle both in an ELISA assay and on immu-
noblots (Fig. 2). Hence, this approach cannot be used for detection
of specific anti-CctA antibodies. Therefore, based on the simple
observations in Fig. 3, we developed a serum haemolysin-
neutralization assay using ovine erythrocytes. In this assay, serum
from all cattle showed specific post-vaccination neutralizing ac-
tivity reaching high levels of approximately 1000 times above
background in samples taken at four weeks post-vaccination, while
no neutralization was measured in the pre-vaccination or imme-
diate post-vaccination samples (Figs. 4 and 5). Results from a pre-
vious study using serum of guinea pigs vaccinated with
recombinant CctA:LTB (LTB was fused to CctA as a biological adju-
vant) neutralized the cytotoxic activity at a dilution of 1:128 [13].
The haemolysin-neutralizing titres obtained with serum of cattle
vaccinated with a commercial vaccine in this study were approxi-
mately 8 times higher than observed in the previous experiment
(Fig. 5A). Hence, vaccination of cattle with a commercial blackleg
vaccine leads to a considerable haemolysin-neutralizing activity in
cattle sera four weeks post-vaccination. Furthermore, guinea pigs
that were vaccinated with blackleg vaccine and survived the sub-
sequent C. chauvoei challenge, successfully passing the official po-
tency test, also show seroconvert to rCctA neutralizing serum 14
days post-vaccination. Collectively, our results show that the
determination of the of haemolysin-neutralizing levels in vacci-
nated animals can be used to assess the potency of blackleg vac-
cines which would eliminate the need for experimental infections
of laboratory animals. The assay developed here is based on re-
combinant CctA andwill be universally applicable since CctA is fully
conserved in C. chauvoei [5].
5. Conclusions
CctA, a major protective antigen of C. chauvoei, is exclusively
found in culture supernatants. This is an important finding for
optimizingproductionprocedures of future blackleg vaccines. In our
Fig. 3. Characteristic haemolytic halo around C. chauvoei colonies due to secreted
CctA is neutralized by anti-CctA. A 10 mL inoculation loop of frozen JF4335 C. chauvoei
stock was spread on to Tryptic soy agar supplemented with 5% sheep blood. Concur-
rently, 10 mL of either anti-CctA serum, anti-rabbit serum or PBS was carefully
dispensed at the designated circled points (X) prior to incubation.
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Fig. 4. CctA haemolysis-neutralizing activity of sera from cattle vaccinated with Bovilis® Blackleg. Data shown are the mean values of 3 independent assays and the standard
deviations are represented by the error bars. The numbers on the x-axis denote the days post-vaccination, while the numbers on y-axis correspond to the haemolysis-neutralizing
titres. The numbers at the top of each graph refers to the cow.
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quest to elucidate the location of CctA we also identified EF-Tu, a
protein that has been shown to be cell surface locatedwithmultiple
virulence associated activities in a plethora of other bacteria,
including the closely related C. perfringes. Thus, EF-Tu expression on
C. chauvoei cell surface warrants further study since it may be an
additional potential target for neutralizing antibodies, cytotoxic
leukocytes or as a subunit vaccination for blackleg, in combination
with CctA. In addition, we used recombinant CctA to develop a po-
tential replacement test for the standard guinea pig challenge po-
tencyassay used for blackleg vaccine batch releases. This novel assay
would remove the current requirement of animal testing.
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